CRDL stock forecast, quote, news & analysis
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease... Show more
Why Cardiol Therapeutics (CRDL) Stock Is Down -33% in the Last 30 Days
Key Takeaways
- CRDL shares have fallen roughly 33% over the trailing 30 days, from about $1.71 in late September to about $1.14 at the most recent close, extending a sharp reversal from early-September highs.
- The pullback reflects a combination of financing-related overhang, warrant activity, and profit-taking after a steep run-up earlier in the period.
- Over the trailing quarter the stock is little changed on balance, but the path has been highly volatile, with a rally above $2.20 followed by a drawdown of roughly 50%.
- Cardiol remains focused on the pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis, which reached its enrollment target ahead of schedule.
- Recent company announcements, including a US$150 million shelf prospectus filing and a warrant exercise, have shaped near-term investor sentiment.
- For additional data, explore the company's Price Targets, Earnings, and Forecast pages.
- Discover AI-driven trading strategies on Tickeron's Trending AI Robots page.
Cardiol Therapeutics (CRDL) Company Overview and Market Position
Cardiol Therapeutics Inc. (NASDAQ: CRDL; TSX: CRDL) is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead candidate, CardiolRx, is an orally administered, pharmaceutically produced cannabidiol formulation designed to modulate inflammasome pathway activation, a process linked to inflammation and fibrosis in pericarditis, myocarditis, and heart failure.
The company is advancing CardiolRx through the pivotal Phase III MAVERIC trial in recurrent pericarditis, an indication for which the U.S. FDA has granted Orphan Drug Designation, and has completed a Phase II ARCHER study in acute myocarditis. A second candidate, CRD-38, is a novel subcutaneous formulation targeting inflammatory heart disease, including heart failure. As a clinical-stage, pre-revenue developer, CRDL is followed primarily for clinical data milestones, regulatory progress, and its balance-sheet position rather than near-term earnings.
Cardiol Therapeutics (CRDL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CRDL declined approximately 33%, from roughly $1.71 in late September to $1.14 at the most recent close. The stock had reached a 52-week high around $2.34 in early September before reversing sharply, and the subsequent weeks brought a steady step-down in price accompanied by elevated trading volume.
The trailing-quarter picture is more nuanced. Measured over roughly three months, the stock is little changed on balance, but that headline figure masks considerable volatility: shares more than doubled from early-July levels near $1.00 to early-September highs above $2.20 before giving back most of those gains. The net result is a round trip in which short-term momentum reversed without a clear directional trend over the full period.
What Drove CRDL Stock Price in the Last 30 Days
The 30-day decline largely represents an unwind of the earlier rally rather than a single negative catalyst. On September 10, 2026, the company filed a preliminary US$150 million base shelf prospectus, including additional program and expense disclosure following a review by staff of the Ontario Securities Commission. A shelf filing can create a perceived dilution overhang, and the disclosure coincided with the stock's initial break lower from its early-September peak.
In mid-September, Cardiol announced over US$7 million in proceeds from warrant exercises and accelerated the remaining outstanding warrants, setting an early expiry date of October 16, 2026. The late-September quarterly report and corporate presentation, combined with broad profit-taking after the sharp run-up, added to selling pressure through October.
What Drove CRDL Stock Performance Over the Last Quarter
The broader quarterly narrative is one of a momentum-driven rally followed by a financing-driven reversal. Through July and August, investors positioned ahead of the Phase III MAVERIC enrollment milestone, lifting the stock from around $1.00 to above $2.20. In late September, the company announced it had achieved its original 110-patient enrollment target ahead of schedule and would expand the trial to up to 150 patients to strengthen the efficacy assessment.
However, financing-related developments — the shelf prospectus filing and the warrant acceleration — introduced supply and dilution concerns that weighed on the shares, while a broader rotation away from speculative small-cap biotechnology names compounded the decline. The result was a rapid retracement that erased most of the quarter's earlier gains.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a platform that offers hundreds of bots trading thousands of tickers. Rather than listing every strategy, the section surfaces the top-performing and most relevant bots, helping users quickly identify approaches drawing current attention. The bots vary in strategy, timeframe, and performance metrics, ranging from short-term technical patterns to longer-horizon signals, so investors can browse options suited to different trading styles. The page is updated to reflect changing market conditions, making it a practical starting point for those interested in systematic, data-driven trading tools.
CRDL Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important variable for CRDL is the topline data readout from the pivotal Phase III MAVERIC trial, which the company has said will support a potential New Drug Application subject to favorable results and regulatory input. Proceeds from recent financings have extended Cardiol's cash runway into the first half of 2028, reducing near-term funding risk while leaving open the possibility of future offerings under the shelf prospectus.
Investors should also monitor the company's quarterly financial results, progress on CRD-38 toward first-in-human development, and any updates on regulatory interactions with the FDA. Broader macro conditions — particularly the interest-rate environment and risk appetite for small-cap biotechnology — remain relevant to how the stock trades around upcoming milestones. These factors carry meaningful uncertainty, and the clinical and regulatory outcomes are not guaranteed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CRDL's Stochastic Oscillator is remaining in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for CRDL just turned positive on October 23, 2026. Looking at past instances where CRDL's MACD turned positive, the stock continued to rise in 43 of 50 cases over the following month. The odds of a continued upward trend are 86%.
Following a +4.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDL advanced for three days, in 178 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRDL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRDL as a result. In 85 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 10-day moving average for CRDL crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CRDL entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.685) is normal, around the industry mean (7.445). P/E Ratio (-2.725) is within average values for comparable stocks, (0.293). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. CRDL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric